Iovance Biotherapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 8 | -$0.42 | -$0.42 | -$0.42 |
Q2 2024 | 6 | -$0.35 | -$0.35 | -$0.35 |
Q3 2024 | 9 | -$0.34 | -$0.24 | -$0.30 |
Q4 2024 | 3 | -$0.27 | -$0.27 | -$0.27 |
Q1 2025 | 5 | -$0.25 | -$0.25 | -$0.25 |
Q2 2025 | 8 | -$0.22 | -$0.22 | -$0.22 |
Q3 2025 | 4 | -$0.20 | -$0.20 | -$0.20 |
Q4 2025 | 5 | -$0.18 | -$0.18 | -$0.18 |
Q1 2026 | 5 | $0.01 | $0.01 | $0.01 |
Q2 2026 | 3 | $0.04 | $0.04 | $0.04 |
Q3 2026 | 3 | $0.06 | $0.06 | $0.06 |
Q4 2026 | 5 | $0.09 | $0.09 | $0.09 |
Iovance Biotherapeutics, Inc. Earnings Date And Information
Iovance Biotherapeutics, Inc. last posted its earnings results on Thursday, August 8th, 2024. The company reported $-0.34 earnings per share for the quarter, topping analysts' consensus estimates of $-0.37 by $0.03. The company had revenue of 31.11 M for the quarter and had revenue of 1.19 M for the year. Iovance Biotherapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.89 diluted earnings per share) and currently has a price-to-earnings ratio of -7.54. Iovance Biotherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Iovance Biotherapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2024 | Q2 2024 | -$0.37 | -$0.34 | 0.03 | $24.59 M | $31.11 M |
05/09/2024 | Q1 2024 | -$0.45 | -$0.42 | 0.03 | $715,000 | |
02/28/2024 | Q4 2023 | -$0.44 | -$0.45 | -0.01 | $482,000 | |
11/07/2023 | Q3 2023 | -$0.46 | -$0.46 | 0 | $4.50 M | $469,000 |
08/08/2023 | Q2 2023 | -$0.81 | -$0.47 | 0.34 | $3.91 M | $238,000 |
05/10/2023 | Q1 2023 | -$0.49 | $0 | |||
02/28/2023 | Q4 2022 | -$0.62 | $0 | |||
11/03/2022 | Q3 2022 | -$0.64 | -$0.63 | 0.01 | $0 | |
08/04/2022 | Q2 2022 | -$0.60 | -$0.63 | -0.03 | $0 | |
05/05/2022 | Q1 2022 | -$0.64 | -$0.58 | 0.06 | $0 | |
02/24/2022 | Q4 2021 | -$0.63 | $0 | |||
11/04/2021 | Q3 2021 | -$0.52 | -$0.55 | -0.03 | $0 | |
08/05/2021 | Q2 2021 | -$0.52 | -$0.53 | -0.01 | $0 | |
05/06/2021 | Q1 2021 | -$0.48 | -$0.51 | -0.03 | $0 | |
02/25/2021 | Q4 2020 | -$0.47 | $0 | |||
11/05/2020 | Q3 2020 | -$0.46 | -$0.40 | 0.06 | $0 | |
08/06/2020 | Q2 2020 | -$0.52 | -$0.47 | 0.05 | $0 | |
05/05/2020 | Q1 2020 | -$0.53 | -$0.55 | -0.02 | $0 | |
02/25/2020 | Q4 2019 | -$0.50 | $0 | |||
11/04/2019 | Q3 2019 | -$0.40 | -$0.40 | 0 | $0 |
Iovance Biotherapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Iovance Biotherapeutics, Inc.'s earnings date?
Iovance Biotherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did Iovance Biotherapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Iovance Biotherapeutics, Inc. (:IOVA) reported $-0.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.37 by $0.03.
-
How can I listen to Iovance Biotherapeutics, Inc.'s earnings conference call?
The conference call for Iovance Biotherapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Iovance Biotherapeutics, Inc.'s conference call transcript?
The conference call transcript for Iovance Biotherapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Iovance Biotherapeutics, Inc. generate each year?
Iovance Biotherapeutics, Inc. (:IOVA) has a recorded annual revenue of $1.19 M.
-
How much profit does Iovance Biotherapeutics, Inc. generate each year?
Iovance Biotherapeutics, Inc. (:IOVA) has a recorded net income of $1.19 M. Iovance Biotherapeutics, Inc. has generated $-1.89 earnings per share over the last four quarters.
-
What is Iovance Biotherapeutics, Inc.'s price-to-earnings ratio?
Iovance Biotherapeutics, Inc. (:IOVA) has a price-to-earnings ratio of -7.54 and price/earnings-to-growth ratio is -1.04.